Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05839002 Completed - Neoplasm, Esophagus Clinical Trials

Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT

Start date: May 21, 2010
Phase:
Study type: Observational

In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).

NCT ID: NCT05825326 Completed - Clinical trials for Myeloproliferative Neoplasm

Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

Start date: January 1, 2012
Phase:
Study type: Observational

The goal of this observational study is to evaluate the epidemiological and clinical-pathological features of Philadelphia-negative myeloproliferative neoplasms through data from medical records

NCT ID: NCT05815056 Completed - Oncology Clinical Trials

Comparaison Between Digital and Drug Induced Sedation in Veinous Access Device Implantation

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare in patients who need an implantation of a veinous access device the sedation with anesthesiologic drugs and with hypnosis using virtual reality material. The main question it aims to answer is: • is hypnosis using virtual reality as safe and powerfull than usual anesthesiologic drugs. Participants will complete a preoperative and postoperative questionnaire. They will be contacted by phone pre and postoperatively. If there is a comparison group: Researchers will compare drug induced sedation and hypnosis induced by virtual reality to see if they are similar in efficacy and sides effects.

NCT ID: NCT05814835 Completed - Clinical trials for Malignant Solid Tumors

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Start date: December 7, 2022
Phase: Phase 1
Study type: Interventional

This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

NCT ID: NCT05812326 Completed - Clinical trials for Advanced Breast Cancer

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Start date: May 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer

NCT ID: NCT05809557 Completed - Oncology Clinical Trials

EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity

Start date: January 9, 2023
Phase: N/A
Study type: Interventional

This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.

NCT ID: NCT05809336 Completed - Clinical trials for Advanced Solid Tumor

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Start date: May 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

We conducted a single-center, prospective randomized ,Parallel controls, open labels Clinical Studies,The study is about Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients with malignant Advanced Solid Tumors .One group was the inosine group , the other group was the non-inosine group.The treatment regimen of inosine group : inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting, and the treatment regimen of non-inosine group : PD-1/PD-L1 inhibitor ± chemotherapy/targeting.The primary study endpoints were overall survival (OS) and progression-free survival PFS, and the secondary study endpoints were objective remission rate (ORR) and disease control rate (DCR) comparing the two groups.

NCT ID: NCT05800249 Completed - Clinical trials for Locally Advanced/Metastatic Solid Tumors

PE0116 Injection in Treatment of Patients With Advanced Solid Tumours

Start date: March 8, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.

NCT ID: NCT05793957 Completed - Clinical trials for Malignant Solid Neoplasm

Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

This clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic, hematologic, and breast cancers. Virtual reality headsets provide the ability for users to explore a simulated, three-dimensional environment with which users can interact. In virtual reality users can play interactive games, enjoy relaxing experiences, and watch immersive videos. The use of VR goggles may help with anxiety management during chemotherapy infusion.

NCT ID: NCT05793281 Completed - Clinical trials for Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Start date: March 10, 2023
Phase:
Study type: Observational

This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational studies, only observations are made without specified advice or interventions. Advanced or recurrent solid tumor harboring an NTRK gene fusion is a rare type of solid cancer caused by specific changes in the genes called NTRK gene fusion, and which has spread to nearby tissues and/or lymph nodes or has returned. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive. The main purpose of this study is to learn more about NTRK gene fusion in people in Japan. To do this, researchers will collect information on the number or percentage of Japanese people with NTRK gene fusion in any solid tumor. The data will come from the national database called C-CAT. They will cover the period from June 2019 until January 2023. Besides this data collection, no further tests or examinations are planned, and no visits are required in this study.